MedTrace Logo

Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma

NCT01768338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-02-10

No results posted yet for this study

Summary

The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Ofatumumab combined with SB-485232

Ofatumumab with escalating doses of SB-485232

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Michael John Robertson

    lead OTHER

Principal Investigators

  • Michael Robertson, MD · Indiana University Melvin and Bren Simon Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-03-31
Completion
2017-08-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768338 on ClinicalTrials.gov